New Drugs Approved In January


Lutathera secured green signal from the FDA on January 26, 2018, for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut and hindgut neuroendocrine tumors in adults.

Developed by Novartis (NVS) company Advanced Accelerator Applications S.A., Lutathera (lutetium Lu 177 dotatate) Injection is a radioactive drug that works by binding to a part of a cell called a somatostatin receptor, which may be present on certain tumors.

This is the first time a radioactive drug has been approved for the treatment of GEP-NETs. Lutathera is a novel drug.

According to the FDA, approximately one out of 27,000 people are diagnosed with GEP-NETs per year. It is to be noted that Apple (AAPL) co-founder Steve Jobs died in 2011 due to pancreatic neuroendocrine tumor.

Baader Helvea analyst Bruno Bulic has pegged peak sales potential of Lutathera at $2 billion. The drug is reportedly set to cost $47,500 per dose.